Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

NewsGuard 100/100 Score

Solasia Pharma K.K. (, a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.

Sancuso is the first and only commercialized extended release granisetron transdermal product. Sancuso was approved for the prevention of chemotherapy-induced nausea and vomiting and launched in the U.S. in 2008. In Japan, granisetron injections and tablets have strong market acceptance with over 50% share of the anti-emetic market.

Solasia also announced a U.S. patent for Sancuso was granted on October 27, 2009 to ProStrakan Group plc who developed and own the worldwide rights to Sancuso. The patent relates to a transdermal patch containing granisetron. “We are very pleased that Prostrakan has obtained the grant of the U.S. patent for Sancuso. This follows patent grants in the EU in 2007 and Japan in 2008, and reaffirms our confidence in the strength of the IP relative to other transdermal granisetron formulations including all such products currently in clinical development in Japan,” stated Solasia president Steve Engen.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness